SEngine Precision Medicine Receives New York State CLEP Approval for PARIS® Test
March 07, 2023 12:04 ET
|
SEngine Precision Medicine, Inc.
From a single sample taken from a patient’s tumor, SEngine scientists can discover which drugs or combinations of drugs are most effective in killing or disabling that individual’s cancerSEngine now...
SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University
September 27, 2022 14:58 ET
|
SEngine Precision Medicine, Inc.
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D...
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS® Test
September 07, 2022 14:42 ET
|
SEngine Precision Medicine, Inc.
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more...
SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments
July 28, 2022 07:00 ET
|
SEngine Precision Medicine, Inc.
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it...
SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors
February 08, 2022 12:30 ET
|
SEngine Precision Medicine, Inc.
SEATTLE and DIJON, France, Feb. 08, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D...
SEngine Precision Medicine Announces New Collaboration to Bring PARIS® Test to Patients with CNS Cancers
November 10, 2021 14:40 ET
|
SEngine Precision Medicine, Inc.
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients...
SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe
October 05, 2021 13:39 ET
|
SEngine Precision Medicine, Inc.
SEATTLE and PARIS, Oct. 05, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and the Institute Gustave Roussy, a leading comprehensive cancer center in Europe, today announced the execution of a...
PARIS® Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer
September 13, 2021 15:17 ET
|
SEngine Precision Medicine, Inc.
SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine announces dramatic results for a 52-year-old patient with terminal ovarian cancer who received the PARIS® Test in early summer...
Strong Predictive Value of Organoid-Based PARIS® Test to Identify Personalized Treatments in Advanced Cancers Presented at 2021 ASCO Annual Meeting
June 08, 2021 08:00 ET
|
SEngine Precision Medicine, Inc.
SEATTLE, June 08, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived tumor organoids employing its CLIA-certified PARIS® Test,...
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS® Test at 2021 ASCO Annual Meeting
April 29, 2021 09:00 ET
|
SEngine Precision Medicine
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today...